The global human papillomavirus vaccine market is anticipated to grow at a significant CAGR of 7.1% during the forecast period 2022-2028. The major drivers attributed to the growth of the market are rising awareness among people regarding the human papillomavirus vaccine. With the rise in the cases of cervical cancer every year, the HPV vaccination is increasing, which is aiding in the growth of the market. Additionally, the government initiatives and programs to provide vaccines to people are supporting in combating the disease.
Browse the full report description “Global Human Papillomavirus Vaccine Market Size, Share, and Trends Analysis Report By Type (Bivalent, Quadrivalent, and Nonavalent) and By Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Vaginal Cancer, Oropharyngeal Cancer, Genital Warts and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/human-papillomavirus-vaccine-hpv-market
Moreover, the major players in the market are going for mergers and acquisitions for new product launches to further contribute to the market growth. For instance, in June 2020, on the eve of the Global Vaccine Summit 2020, vaccine manufacturers Merck & Co. inc., GlaxoSmithKline PLC, Innovax Pharmaceutical Ltd., and Serum Institute of India Pvt. Ltd., ramped up human papillomavirus vaccine (HPV) supply availability for Gavi-supported countries, which have amongst the highest cervical cancer burdens globally.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - including,., Merck & Co. inc., GlaxoSmithKline PLC, Innovax Pharmaceutical Ltd., Serum Institute of India Pvt. Ltd., AstraZeneca PLC, and Johnson & Johnson Services, Inc., among others
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Human Papillomavirus Vaccine Market Report Segment
By Type
By Indication
Global Human Papillomavirus Vaccine Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World